.Competing passions.J.L.M. mentions institutional research funding coming from AstraZeneca, Seagen, Sermonix as well as Olema and advisory as well as seeking advice from parts along with Pfizer, Seagen, Sermonix, Novartis, Stemline, AstraZeneca, Olema, GlaxoSmithKline and also GE Medical Care. C.Y.
mentions institutional study give coming from NCI/NIH earnings support and travel repayment from QLHC an USA patent labelled u00e2 $ Breast cancer cells action prediction subtypesu00e2 $ (no. 18/174,491) as well as Educational Institution of California Innovator Reveal. H.S.R.
reports institutional investigation assistance from AstraZeneca, Daiichi Sankyo, Inc., F. Hoffmannu00e2 $ “La Roche AG/Genentech, Inc., Gilead Sciences, Inc., Lilly Merck and Co., Novartis Pharmaceuticals Company, Pfizer, Stemline Therapies, OBI Pharma, Ambrx, Greenwich Pharma and also consultatory as well as speaking to tasks along with Chugai, Puma, Sanofi, Napo and also Mylan. R.N.
documents analysis backing from Arvinas, AstraZeneca, BMS, Corcept Therapeutics, Genentech/Roche, Gilead, GSK, Merck, Novartis, OBI Pharma, OncoSec, Pfizer, Relay, Seat Genetics, Sun Pharma as well as Taiho and also consultatory jobs along with AstraZeneca, BeyondSpring, Daiichi Sankyo, Particular Sciences, Fujifilm, GE, Gilead, Guardant Wellness, Infinity, iTeos, Merck, Moderna, Novartis, OBI, OncoSec, Pfizer, Sanofi, Seagen and Stemline. M.D. discloses research gives coming from NIH/NCI and NIH/NIA, as well as deals coming from PCORI.
A.J.C. discloses institutional investigation backing from Merck, Amgen, The Puma Corporation, Seagen, Pfizer and also Olema as well as advisory tasks with AstraZeneca and also Genentech. A.Z.
states institutional investigation backing from Merck, honoraria for Medscape and also participation on Pfizer Advisory Board. A.S.C. states institutional research study financing coming from Novartis and also Lilly.
A.D.E. discloses support coming from Scorpion, Infinity and Deciphera. E.S.-R.
documents grants coming from V Groundwork, NIH, Susan G. Komen institutional study funding from GSK, Seagen, Pfizer, Lilly consulting and gratuity coming from Novartis, Merck, Seagen, AstraZeneca, Lilly Cancer Cells Understanding Network Panel member and also assistance from ASCO and also NCCN. J.C.B.
mentions institutional research backing coming from Eli Lilly and Teamwork, engagement on the Data Protection Observing Committee of Cairn Surgical and also gratuity coming from PER, PeerView, OncLive, EndoMag and also UpToDate. C.V. discloses institutional study funding from Pfizer, Seagen, H3 Biomedicine/Eisai, AstraZeneca, CytomX study financing to previous company coming from Genentech, Roche, Pfizer, Incyte, Pharmacyclics, Novartis, TRACON Pharmaceuticals, Innocrin Pharmaceuticals, Zymeworks and H3 Biomedicine advisory and also speaking to parts with Guidepoint, Novartis, Seagen, Daiichi Sankyo, AstraZeneca and also Cardinal Health overdue consulting along with Genentech as well as engagement in non-CME task with Gilead, AstraZeneca.
C.O. states consulting costs from AstraZeneca, Guardant Health And Wellness and Jazz Pharmaceuticals. K.S.A.
reports institutional study funding coming from AstraZeneca, Daiichi Sankyo, Seat Genetics and also QLHC Independent Data and also Protection Observing board at Seat Genes. K.M.K. mentions advising and specialist functions for Eli Lilly, Pfizer, Novartis, AstraZeneca, Daiichi Sankyo, The Puma Corporation, 4D Pharma, OncoSec, Immunomedics, Merck, Seagen, Mersana, Menarini Silicon Biosystems, Myovant, Takeda, Biotheranostics, Regor, Gilead, Introduction Therapeutics, RayzeBio, effect Therapeutics and Cullinan Oncology and also files institutional investigation funding coming from Genentech/Roche, Novartis, Eli Lilly, AstraZeneca, Daiichi Sankyo as well as Ascentage.
C.I. reports institutional analysis financing coming from Tesaro/GSK, Seattle Genetics, Pfizer, AstraZeneca, BMS, Genentech, Novartis and also Regeneron working as a consultant tasks along with AstraZeneca, Genentech, Gilead, ION, Merck, Medscape, MJH Holdings, Novartis, Pfizer, The Puma Corporation and also Seagen and also royalties coming from Wolters Kluwer (UptoDate) and also McGraw Hillside (Goodman as well as Gillman). J.T.
works as institutional key investigator for scientific test along with User-friendly Surgical publisher top for abdominal muscle, CGSO, RATING, Breast Education And Learning Board Keep Track Of Forerunner, ASCO SESAP 19 as well as Bosom Co-Chair, ACS. A.T. possesses stock at Johnson and also Johnsons, Gilead, Bristol Myers Squibb, mentions engagement on Pfizer Advisory Board: AstraZeneca and documents institutional investigation funding coming from Merck and also Sanofi and aristocracies coming from UptoDate.
R.B. reports a consultancy part at Genentech and stock ownership at Cerus Corp. K.Y.
received research assistance unrelated to this job and also paid out to the establishment coming from Pfizer, Gilead, Seagen, Dantari Pharmaceuticals, Treadwell Therapies, as well as Relay Rehabs help from American Cancer cells Culture IRG give no. IRG-19-230-48-IRG, UC San Diego Moores Cancer Cells Center, Specialized Cancer Facility help grant NIH/NCI P30CA023100, Curebound Exploration Honor (2023, 2024). T.S.
mentions honoraria from Hologic. L.P. reports institutional research backing from Susan Komen Groundwork, Breast Cancer Investigation Foundation, NCI, Pfizer, AstraZeneca, Menarini/Stemline, Bristol Myers Squibb, Merck and Co.
consulting expenses from AstraZeneca, Merck, Novartis, Genentech, Natera, Personalis, Precise Sciences and also Stemline/Menarini patent labelled u00e2 $ Method of assessing recurring cancer as well as anticipating client survivalu00e2 $ (no. 7711494) as well as Information as well as Security Monitoring Panel participant of the DYNASTY Breast02, OPTIMA and also PARTNER trials. M.S.T.
reports institutional research study financing coming from Lilly, Gilead Sciences, Phoenix Az Molecular Styles, AstraZeneca, Regeneron, Merck and also Novartis. A.L.A., P.B. and also P.N.
are employees of QLHC. G.L.H. states institutional investigation give coming from NIH (1R01CA255442).
W.F.S. states portions of IONIS Pharmaceuticals and Eiger Biopharmaceuticals, obtained consulting charges coming from AstraZeneca, is a cofounder with equity in Delphi Diagnostics as well as issued licenses for (1) a strategy to compute residual cancer cells trouble and also (2) genomic trademark to assess sensitiveness to hormonal therapy. J.P.
reports honoraria from Techniques in Clinical Researchu00e2 $” professors SCION shop help from ASCO as well as supporter scholarship AACRu00e2 $” SSP system VIVLI, U Wisc SPOREu00e2 $” EAB, QuantumLEADu00e2 $” COVID DSMB, PCORIu00e2 $” customer and I-SPY proponent lead. P.P. reports institutional investigation financing coming from Genentech/Roche, Fabre-Kramer, Advanced Cancer Therapies, Caris Centers of Quality, Pfizer, Pieris Pharmaceuticals, Cascadian Rehab, Bolt, Byondis, Seagen, Orum Rehabs and also Carisma Therapeutics consulting charges from Individualized Cancer cells Treatment, OncoPlex Diagnostics, Immunonet BioSciences, Pfizer, HERON, The Puma Corporation Medical, Sirtex, CARIS Life scientific researches, Juniper, Screw Biotherapeutics as well as AbbVie gratuity from DAVA Oncology, OncLive/MJH Life Sciences, Frontiersu00e2 $” author, SABCS and ASCO Speakersu00e2 $ Bureau: Genentech/Roche (previous) United States patent no.
8486413, United States license no. 8501417, USA patent no. 9023362, USA license no.
9745377 unremunerated tasks along with Pfizer, Seagen as well as Jazz. R.A.S. states institutional study funding from OBI Pharma, QLHC, AstraZeneca and Gilead, serves on AstraZeneca and also Stemline Advisory Boards as well as Gilead Speakeru00e2 $ s Bureau and records working as a consultant function with QLHC.
A.D. states institutional analysis financing coming from Novartis, Pfizer, Genentech and also NeoGenomics Course Office Chair, Scientific Advisory Board, ASCO. D.Y.
states research financing coming from NIH/NCI P30 CA 077598, P01 CA234228-01 as well as R01CA251600, consulting costs from Martell Diagnostics, and also gratuity as well as trip for talking at the u00e2 $ Global Bosom Cancer Cells Conference.u00e2 $ L.J.v.V. is a founding advisor as well as shareholder of Exai Biography and also is a part time staff member and owns inventory in Agendia. N.M.H.
reports institutional analysis funding coming from NIH. L.J.E. reports financing from Merck and also Co., involvement on an advisory board for Blue Cross Blue Defense and also individual expenses from UpToDate and is an unpaid board member of QLHC.
The various other writers declare no contending passions.